Enzymatica AB (publ)
STO:ENZY
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.73
4.195
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ENZY stock under the Base Case scenario is 1.83 SEK. Compared to the current market price of 1.8 SEK, Enzymatica AB (publ) is Undervalued by 2%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Enzymatica AB (publ)
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ENZY cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Enzymatica AB (publ)
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Enzymatica AB (publ)
Balance Sheet Decomposition
Enzymatica AB (publ)
Current Assets | 128.5m |
Cash & Short-Term Investments | 96.9m |
Receivables | 19.3m |
Other Current Assets | 12.4m |
Non-Current Assets | 83.4m |
Long-Term Investments | 2.4m |
PP&E | 14.3m |
Intangibles | 66.7m |
Other Non-Current Assets | 1k |
Current Liabilities | 10.9m |
Accounts Payable | 9.7m |
Other Current Liabilities | 1.2m |
Non-Current Liabilities | 11.5m |
Long-Term Debt | 1.3m |
Other Non-Current Liabilities | 10.2m |
Earnings Waterfall
Enzymatica AB (publ)
Revenue
|
44.2m
SEK
|
Cost of Revenue
|
-14.9m
SEK
|
Gross Profit
|
29.4m
SEK
|
Operating Expenses
|
-81.5m
SEK
|
Operating Income
|
-52.1m
SEK
|
Other Expenses
|
-1.8m
SEK
|
Net Income
|
-54m
SEK
|
Free Cash Flow Analysis
Enzymatica AB (publ)
SEK | |
Free Cash Flow | SEK |
ENZY Profitability Score
Profitability Due Diligence
Enzymatica AB (publ)'s profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Enzymatica AB (publ)'s profitability score is 18/100. The higher the profitability score, the more profitable the company is.
ENZY Solvency Score
Solvency Due Diligence
Enzymatica AB (publ)'s solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Enzymatica AB (publ)'s solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ENZY Price Targets Summary
Enzymatica AB (publ)
According to Wall Street analysts, the average 1-year price target for ENZY is 3.96 SEK with a low forecast of 2.71 SEK and a high forecast of 5.34 SEK.
Dividends
Current shareholder yield for ENZY is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ENZY Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Enzymatica AB engages in the research, development, and sale of medical technology products. The company is headquartered in Lund, Skane and currently employs 26 full-time employees. The company went IPO on 2011-06-14. The company researches, develops and registers enzyme-based health and wellbeing products. The firm uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The firm conducts clinical studies of ColdZyme Munspray, a cold medicine. The company operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.
Contact
IPO
Employees
Officers
The intrinsic value of one ENZY stock under the Base Case scenario is 1.83 SEK.
Compared to the current market price of 1.8 SEK, Enzymatica AB (publ) is Undervalued by 2%.